Background

The rapid vaccination campaign against COVID-19 in Israel relied on the BNT162b2 vaccine. We performed a longitudinal analysis of multiple cohorts, using individual data, to evaluate the effectiveness of the vaccine against new and breakthrough cases.

Methods

We estimated vaccine effectiveness (VE) for 27 consecutive cohorts, each comprised of individuals vaccinated on specific days. VE against new COVID-19 cases was evaluated for five SARS-CoV-2-related outcomes: infection, symptomatic disease, hospitalisation, severe/critical disease and death. For breakthrough cases, rate reduction was evaluated for hospitalisation, severe/critical disease and death. Outcomes were evaluated at predetermined time-periods after vaccination, the last one dedicated to individuals who became SARS-CoV-2-positive 22–28 days after the second dose.

Findings

The highest VE estimates against new cases in ≥16 year old individuals, for all outcomes, were reached at the 15–21 day period after the second dose, ranging between 97.7% (95% CI: 95.9–98.7%) for deaths and 98.6% (95% CI: 97.8–99.1%) for severe/critical disease. VE estimates of the 14–20 day period after the first dose ranged between 54.3% (95% CI: 50.6–57.8%) for infection and 77.3% (95% CI: 71.2–82.1%) for severe/critical disease. VE rose more slowly among ≥80 year old individuals. Rate reductions of breakthrough complications were highest at the 22–28 day period after the second dose, ranging between 47.4% (95% CI: 4.3–71.2%) for death and 66.2% (95% CI: 44.2–79.6%) for severe/critical disease.

Interpretation

The BNT162 vaccine is highly effective in preventing new SARS-CoV-2 cases. Among ≥80 year old individuals, high effectiveness develops more slowly. In breakthrough cases, vaccination reduces complications and death.

Funding

None.

中文翻译：

---

BNT162b2 疫苗对新的 COVID-19 病例和突破性病例并发症的有效性：使用个性化数据的全国性回顾性纵向多队列分析

背景

以色列针对 COVID-19 的快速疫苗接种运动依赖于 BNT162b2 疫苗。我们使用个人数据对多个队列进行了纵向分析，以评估疫苗对新病例和突破性病例的有效性。

方法

我们估计了 27 个连续队列的疫苗有效性 (VE)，每个队列由在特定日期接种疫苗的个体组成。评估了针对新 COVID-19 病例的 VE 的五种 SARS-CoV-2 相关结果：感染、症状性疾病、住院治疗、严重/危重疾病和死亡。对于突破性病例，对住院、严重/危重疾病和死亡的比率降低进行了评估。在接种疫苗后的预定时间段评估结果，最后一个专门用于在第二次接种后 22-28 天成为 SARS-CoV-2 阳性的个体。

发现

对于所有结局，≥16 岁个体新病例的最高 VE 估计值在第二次给药后的 15-21 天期间达到，范围在 97.7%（95% CI：95.9-98.7%）死亡和 98.6 % (95% CI: 97.8–99.1%) 用于严重/危重疾病。首次给药后 14-20 天期间的 VE 估计值在感染的 54.3%（95% CI：50.6-57.8%）和严重/危重疾病的 77.3%（95% CI：71.2-82.1%）之间。VE 在 80 岁以上的人中上升得更慢。在第二次给药后的 22-28 天期间，突破性并发症的降低率最高，范围在死亡的 47.4%（95% CI：4.3-71.2%）和严重的 66.2%（95% CI：44.2-79.6%）之间/重病。

解释

BNT162 疫苗在预防新的 SARS-CoV-2 病例方面非常有效。在≥80岁的个体中，高效能发展更慢。在突破性病例中，接种疫苗可减少并发症和死亡。

资金

没有任何。